

Special Issue

Advanced Research in Proteinopathies

Message from the Guest Editors

Proteinopathies are a family of diseases characterized by the accumulation of specific proteins within neurons or in the brain parenchyma that lead to synaptic dysfunction and neuronal loss. Examples for proteinopathies are Alzheimer's disease, Parkinson's disease, Lewy body disease, amyotrophic lateral sclerosis and fronto-temporal lobar degeneration. Typically, in a disease condition, the unstructured proteins change their conformation leading to small oligomers that eventually aggregate into higher-order structures. Over the years, the structural and morphological features of several protein aggregate species have been investigated, as well as the cellular events that lead to neuronal dysfunction. Moreover, a number of potential therapeutic strategies have been explored, including small molecules, antibodies and natural compounds, some of them showing promising outcomes. This Special Issue welcomes the submission of original research papers and reviews on the most advanced developments in the above-mentioned topics, with special attention on possible therapeutic approaches targeting misfolded proteins.

Guest Editors

Dr. Claudia Capitini

LENS-European Laboratory for Non-Linear Spectroscopy, Sesto Fiorentino, Italy

Dr. Manuela Leri

Department of Biomedical, Experimental and Clinical Sciences "Mario Serio", University of Florence, Viale Morgagni 50, 50134 Florence, Italy

Deadline for manuscript submissions

closed (31 January 2025)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 5.2
Indexed in PubMed



mdpi.com/si/192163

Biomedicines

MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 5.2
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2024).